FIRST-LINE CRIZOTINIB VS PEMETREXED plus CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK plus NSCLC IN PROFILE 1014

被引：3
|
作者：
Nakagawa, Kazuhiko [1 ]
Kim, Dong-Wan [2 ]
Wu, Yi-Long [3 ]
Solomon, Benjamin J. [4 ]
Mekhail, Tarek [5 ]
Felip, Enriqueta [6 ]
Cappuzzo, Frederico [7 ]
Blackhall, Fiona [8 ]
Usari, Tiziana [9 ]
Mok, Tony [10 ]
机构：
[1] Kinki Univ, Osaka, Japan
[2] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[3] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Florida Hosp Canc Inst, Orlando, FL USA
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Osped Riuniti, Livorno, Italy
[8] Christie Hosp, Manchester, Lancs, England
[9] Pfizer Oncol, Milan, Italy
[10] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu395.1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK plus advanced non-squamous non-small cell lung cancer (NSCLC).
    Lu, Shun
    Mok, Tony
    Lu, You
    Zhou, Jianying
    Shi, Yuankai
    Sriuranpong, Virote
    Ho, James C. M.
    Ong, Choo Khoon
    Tsai, Chun-Ming
    Chung, Chin-Hee
    Wilner, Keith D.
    Tang, Yiyun
    Masters, Elizabeth
    Selaru, Paulina
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
    Mok, Tony
    Kim, Dong-Wan
    Wu, Yi-Long
    Solomon, Benjamin J.
    Nakagawa, Kazuhiko
    Mekhail, Tarek
    Felip, Enriqueta
    Cappuzzo, Federico
    Paolini, Jolanda
    Usari, Tiziana
    Tursi, Jennifer
    Blackhall, Fiona Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] First-Line Nivolumab plus Nab-Paclitaxel plus Carboplatin (C) in Advanced NSCLC
    Waterhouse, David
    Derosa, William
    Fraser, Cindy Duval
    Gutierrez, Martin
    Ko, Amy
    Ong, Teng Jin
    Pierce, Daniel
    Stergiopoulos, Sotirous
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S427 - S428
  • [4] First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation
    Shi, Yuankai
    Wang, Lin
    Han, Baohui
    Li, Wei
    Yu, Ping
    Liu, Yunpeng
    Ding, Cuimin
    Song, Xia
    Ma, Zhiyong
    Ren, Xinling
    Feng, Jifeng
    Zhang, Helong
    Chen, Gongyan
    Wu, Ning
    Han, Xiaohong
    Yao, Chen
    Song, Yong
    Zhang, Shucai
    Ding, Lieming
    Tan, Fenlai
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S205 - S206
  • [5] Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: Updated results from PROFILE 1014
    Mok, T. S. K.
    Kim, D-W.
    Wu, Y-L.
    Nakagawa, K.
    Mekhail, T.
    Felip, E.
    Cappuzzo, F.
    Paolini, J.
    Usari, T.
    Wilner, K.
    Blackhall, F.
    Solomon, B. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Pemetrexed mit Cisplatin in der Erstlinientherapie des NSCLCPemetrexed plus cisplatin as first-line therapy for NSCLC
    N.J. Dickgreber
    Der Pneumologe, 2009, 6 (3): : 176 - 178
  • [7] Primary results from the China cohort of IMpower132: Atezolizumab (atezo) plus carboplatin (carbo) or cisplatin (cis) plus pemetrexed (pem) as first-line therapy in advanced NSCLC
    Lu, S.
    Fang, J.
    Wang, Z.
    Fan, Y.
    Liu, Y.
    He, J.
    Cao, B.
    Zhou, J.
    Hu, J.
    Xia, J.
    Liu, W.
    Shi, J.
    Yi, J.
    Cao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S753
  • [8] Pemetrexed with Cisplatin as First-line Therapy for NSCLC
    Dickgreber, N. J.
    PNEUMOLOGE, 2009, 6 (03): : 176 - 178
  • [9] Cost Analysis of the Management of CNS Metastases in Patients with Advanced ALK plus NSCLC: Alectinib vs Crizotinib
    Massuti, B.
    Lazaro, M.
    Isla, D.
    Gordo, R.
    Ruiz De Alda, L.
    Ortega, N.
    Oyaguez, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S856 - S856
  • [10] A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
    Xiong, J.
    Li, J.
    Deng, J.
    Zhang, W.
    Wang, H.
    Zeng, L.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S676
12345